Profile data is unavailable for this security.
About the company
Catalent, Inc. is engaged in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. The Company’s Biologics segment provides development and manufacturing of biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells (iPSCs); oncolytic viruses, and vaccines. It also provides formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges, and analytical development and testing services for large molecules. The Company’s Pharma and Consumer Health segment comprises capabilities for complex oral solids, softgel formulations, Zydis fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms, and clinical trial development and supply services.
- Revenue in USD (TTM)4.10bn
- Net income in USD-1.30bn
- Incorporated2007
- Employees17.80k
- LocationCatalent Inc14 Schoolhouse RdSOMERSET 08873-1213United StatesUSA
- Phone+1 (732) 537-6200
- Fax+1 (732) 537-6480
- Websitehttps://www.catalent.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KBR Inc | 6.96bn | -265.00m | 8.38bn | 34.00k | -- | 6.08 | -- | 1.20 | -2.03 | -2.03 | 50.04 | 10.24 | 1.25 | -- | 5.91 | 204,588.20 | -4.69 | 0.4725 | -6.77 | 0.6678 | 14.05 | 12.18 | -3.75 | 0.4122 | -- | 1.14 | 0.5679 | 340.00 | 5.97 | 7.20 | -240.21 | -- | 36.31 | 11.03 |
| Roivant Sciences Ltd | 123.24m | 4.35bn | 8.41bn | 904.00 | 2.06 | 1.38 | 1.97 | 68.26 | 5.07 | 5.23 | 0.1597 | 7.57 | 0.0259 | -- | 3.57 | 136,328.50 | 89.08 | -- | 105.17 | -- | 87.57 | -- | 3,439.02 | -- | 27.77 | -- | 0.0638 | -- | 10.84 | -- | -32.93 | -- | -- | -- |
| Legend Biotech Corp (ADR) | 285.14m | -518.25m | 8.88bn | 1.80k | -- | 7.10 | -- | 31.15 | -2.95 | -2.95 | 1.62 | 6.88 | 0.1794 | 9.68 | 5.70 | 158,412.80 | -32.60 | -37.71 | -38.89 | -47.19 | 49.42 | -- | -181.75 | -286.51 | 6.83 | -24.23 | 0.208 | -- | 143.70 | 42.15 | -16.11 | -- | 1.57 | -- |
| Repligen Corp | 638.76m | 41.58m | 8.99bn | 1.78k | 223.36 | 4.55 | 81.97 | 14.07 | 0.7207 | 0.7207 | 11.27 | 35.35 | 0.2388 | 1.47 | 5.31 | 358,252.40 | 1.55 | 4.38 | 1.74 | 5.03 | 49.35 | 55.43 | 6.51 | 15.91 | 5.75 | -- | 0.2272 | 0.00 | -20.31 | 26.91 | -77.64 | 20.13 | 24.99 | -- |
| BIO-TECHNE Corp | 1.14bn | 224.12m | 9.86bn | 3.05k | 45.25 | 5.02 | 29.49 | 8.61 | 1.39 | 1.39 | 7.09 | 12.50 | 0.4495 | 2.21 | 5.84 | 375,409.50 | 8.80 | 9.57 | 9.28 | 10.20 | 67.13 | 67.35 | 19.58 | 21.91 | 3.03 | 18.86 | 0.1854 | 24.19 | 2.81 | 12.07 | 4.88 | 25.13 | 12.81 | 0.00 |
| Catalent Inc | 4.10bn | -1.30bn | 10.11bn | 17.80k | -- | 2.75 | -- | 2.47 | -7.18 | -7.18 | 22.52 | 20.37 | 0.3878 | 4.09 | 3.00 | 230,224.70 | -12.32 | 2.88 | -14.02 | 3.26 | 17.94 | 31.03 | -31.77 | 6.35 | 1.71 | -0.625 | 0.5758 | 0.00 | -11.22 | 11.59 | -153.00 | -- | 26.69 | -- |
| Natera Inc | 1.08bn | -434.80m | 10.91bn | 3.28k | -- | 14.11 | -- | 10.08 | -3.80 | -3.80 | 9.41 | 6.40 | 0.7634 | 15.49 | 4.14 | 329,851.00 | -30.66 | -36.17 | -39.20 | -46.60 | 45.52 | 45.88 | -40.16 | -56.15 | 3.96 | -- | 0.3219 | -- | 31.99 | 33.26 | 20.63 | -- | 58.81 | -- |
| Sarepta Therapeutics Inc | 1.24bn | -535.98m | 11.06bn | 1.31k | -- | 12.86 | -- | 8.90 | -6.15 | -6.15 | 13.46 | 9.17 | 0.389 | 0.5708 | 4.04 | 946,222.30 | -16.77 | -21.63 | -20.94 | -25.75 | 87.91 | 86.65 | -43.11 | -77.05 | 3.45 | -- | 0.5903 | -- | 33.26 | 32.80 | 23.81 | -- | 6.30 | -- |
| United Therapeutics Corporation | 2.33bn | 984.80m | 11.07bn | 1.17k | 11.87 | 1.85 | 10.67 | 4.76 | 19.82 | 19.82 | 46.83 | 127.23 | 0.3523 | 2.41 | 9.32 | 1,992,723.00 | 14.91 | 10.38 | 16.33 | 11.27 | 88.94 | 91.47 | 42.31 | 29.25 | 4.28 | -- | 0.1047 | 0.00 | 20.20 | 7.41 | 35.40 | 10.89 | 4.55 | -- |
| Exact Sciences Corp | 2.50bn | -204.15m | 11.48bn | 6.50k | -- | 3.65 | 4,667.10 | 4.59 | -1.14 | -1.14 | 13.81 | 17.34 | 0.3937 | 5.32 | 13.82 | 384,579.40 | -3.22 | -9.71 | -3.47 | -10.60 | 73.83 | 74.10 | -8.17 | -28.21 | 2.07 | -- | 0.4311 | -- | 19.93 | 40.63 | 67.26 | -- | -3.71 | -- |
| Incyte Corp | 3.70bn | 597.60m | 11.84bn | 2.52k | 19.94 | 2.28 | 17.40 | 3.20 | 2.64 | 2.64 | 16.36 | 23.14 | 0.5855 | 4.43 | 5.32 | 1,464,203.00 | 9.47 | 9.07 | 11.69 | 11.02 | 93.71 | 94.97 | 16.17 | 13.68 | 3.69 | -- | 0.0062 | 0.00 | 8.87 | 14.45 | 75.42 | 40.41 | -15.06 | -- |
| Medpace Holdings Inc | 1.89bn | 282.62m | 11.85bn | 5.90k | 43.09 | 20.99 | 38.33 | 6.28 | 8.87 | 8.87 | 59.24 | 18.22 | 1.25 | -- | 6.84 | 319,634.30 | 18.80 | 13.94 | 44.16 | 23.18 | 27.81 | 28.84 | 15.00 | 15.23 | -- | 690.22 | 0.00 | -- | 29.17 | 21.76 | 15.26 | 31.17 | 17.99 | -- |
| Charles River Lbrtrs ntrntl Inc | 4.13bn | 474.62m | 11.85bn | 20.00k | 24.93 | 3.28 | 14.92 | 2.87 | 9.23 | 9.23 | 80.25 | 70.06 | 0.5228 | 8.19 | 5.39 | 206,470.50 | 6.08 | 6.46 | 7.09 | 7.62 | 36.89 | 36.99 | 11.63 | 11.58 | 1.16 | 4.97 | 0.4203 | 0.00 | 3.86 | 12.75 | -2.39 | 16.69 | 17.86 | -- |
Data as of Apr 18 2024. Currency figures normalised to Catalent Inc's reporting currency: US Dollar USD
62.01%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2023 | 19.43m | 10.75% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2023 | 19.08m | 10.56% |
| Janus Henderson Investors US LLCas of 31 Dec 2023 | 13.23m | 7.32% |
| Nomura Securities Co., Ltd. (Private Banking)as of 31 Dec 2023 | 11.49m | 6.36% |
| T. Rowe Price Investment Management, Inc.as of 31 Dec 2023 | 11.21m | 6.20% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 9.49m | 5.25% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 8.17m | 4.52% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 7.46m | 4.13% |
| Veritas Asset Management LLPas of 31 Dec 2023 | 6.47m | 3.58% |
| Cadian Capital Management LPas of 31 Dec 2023 | 6.06m | 3.36% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
